Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

J Clin Oncol. 2010 Jan 20;28(3):437-44. doi: 10.1200/JCO.2009.24.7999. Epub 2009 Dec 14.

PMID:
20008626
2.

Thrombopoietin mimetics for patients with myelodysplastic syndromes.

Dodillet H, Kreuzer KA, Monsef I, Skoetz N.

Cochrane Database Syst Rev. 2017 Sep 30;9:CD009883. doi: 10.1002/14651858.CD009883.pub2. Review.

PMID:
28962071
3.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
4.

Romiplostim.

Kuter DJ.

Cancer Treat Res. 2011;157:267-88. doi: 10.1007/978-1-4419-7073-2_16. Review.

PMID:
21052962
5.

Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.

Newland A.

Eur J Haematol Suppl. 2009 Mar;(71):20-5. doi: 10.1111/j.1600-0609.2008.01209.x. Review.

PMID:
19200304
6.

Thrombocytopenia in patients with myelodysplastic syndromes.

Bryan J, Jabbour E, Prescott H, Kantarjian H.

Semin Hematol. 2010 Jul;47(3):274-80. doi: 10.1053/j.seminhematol.2010.02.006. Review.

7.

Romiplostim: a novel thrombopoiesis-stimulating agent.

Perreault S, Burzynski J.

Am J Health Syst Pharm. 2009 May 1;66(9):817-24. doi: 10.2146/ajhp080524. Review.

PMID:
19386944
8.

Thrombopoiesis-stimulating agents and myelodysplastic syndromes.

Brierley CK, Steensma DP.

Br J Haematol. 2015 May;169(3):309-23. doi: 10.1111/bjh.13285. Epub 2015 Feb 6. Review.

PMID:
25659186
9.

Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.

Prica A, Sholzberg M, Buckstein R.

Br J Haematol. 2014 Dec;167(5):626-38. doi: 10.1111/bjh.13088. Epub 2014 Aug 26. Review.

PMID:
25155450
10.

The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.

Tiu RV, Sekeres MA.

Expert Opin Biol Ther. 2008 Jul;8(7):1021-30. doi: 10.1517/14712598.8.7.1021 . Review.

PMID:
18549331
11.

The development of romiplostim for patients with immune thrombocytopenia.

Molineux G.

Ann N Y Acad Sci. 2011 Mar;1222:55-63. doi: 10.1111/j.1749-6632.2011.05975.x. Review.

PMID:
21434943
12.

What is the role of novel thrombopoietic agents in the management of acute leukemia?

Kuter DJ.

Best Pract Res Clin Haematol. 2016 Dec;29(4):372-378. doi: 10.1016/j.beha.2016.10.013. Epub 2016 Oct 19. Review.

PMID:
27890262
13.

Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A.

Leukemia. 2016 Mar;30(3):536-44. doi: 10.1038/leu.2015.297. Epub 2015 Oct 26. Review.

PMID:
26500138
14.

Romiplostim.

Frampton JE, Lyseng-Williamson KA.

Drugs. 2009;69(3):307-17. doi: 10.2165/00003495-200969030-00006. Review.

PMID:
19275274
15.

Revisiting use of growth factors in myelodysplastic syndromes.

Newman K, Maness-Harris L, El-Hemaidi I, Akhtari M.

Asian Pac J Cancer Prev. 2012;13(4):1081-91. Review.

16.

Thrombocytopenia and platelet transfusion in the neonate.

Cremer M, Sallmon H, Kling PJ, Bührer C, Dame C.

Semin Fetal Neonatal Med. 2016 Feb;21(1):10-8. doi: 10.1016/j.siny.2015.11.001. Epub 2015 Dec 19. Review.

PMID:
26712568
17.

[Supportive therapy for myelodysplastic syndrome (MDS). Indispensable pillar in the multimodal treatment concept].

Göbel A, Lubrich B.

Pharm Unserer Zeit. 2010 May;39(3):228-33. doi: 10.1002/pauz.201000370. Review. German. No abstract available.

PMID:
20425777
18.

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia.

Vishnu P, Aboulafia DM.

J Blood Med. 2016 May 25;7:99-106. doi: 10.2147/JBM.S80646. eCollection 2016. Review.

19.

Current and future management options for myelodysplastic syndromes.

Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H.

Drugs. 2010 Jul 30;70(11):1381-94. doi: 10.2165/11537920-000000000-00000. Review.

PMID:
20614946

Supplemental Content

Support Center